Multiple Myeloma - Survival Rate Statistics by Hospital

Myeloma Survival Rate Statistics by Hospital and Specialist

Multiple Myeloma is a blood cancer of the plasma cells(white blood cells found in the bone marrow) that requires treatment support from a skilled multiple myeloma specialist to provide you the best possible prognosis for the longest life expectancy. This site provides the most relevant multiple myeloma survival rate statistics that can be found or developed to provide multiple myeloma patients with survival rates by hospital,©grp specialist,©grp and region. We believe that having a multiple myeloma specialist on your team is critical to improve your life expectancy,©grp and having one as your doctor or a consult with a multiple myeloma specialist and continued involvement with a multiple myeloma specialist mentioned on this site or one you can find is one of the most important things you can do to ensure your care results in the best possible life expectancy. We ask that doctors across the US and the globe provide their currently available multiple myeloma survival rates or if not yet available then provide 2 and 4 year multiple myeloma survival rates to this site so that multiple myeloma patients can make some informed decisions about their doctors and the facilities that they choose for their care. I believe every patient has a right to know how his doctor or center compares,©grp and this data should be available or made available.

The SEER data from the National Cancer Institute indicates that there is an average of 55.6% for 3 year survival,©grp where as the Mayo Clinic reports their 3 year survival rate at close to 90%,©grp and Dr. Palumbo of Italy shows a non transplant clinical trial of older patients with a 3 year survival of 89%. Also a doctor in LA,©grp Dr. Berenson has shown 5 year survival of 89.7%*,©grp and this is much better than the SEER data of 41%. Therefore,©grp you are nearly 5.7* times more likely to survive in his care than in the average facility. UAMS is an excellent center and publishes their average life expectancy of almost 9 years versus the recent SEER life expectancy of 4 years. We believe this type of information,©grp if available,©grp will be invaluable to all multiple myeloma patients. God bless you all who have to be on this journey! You can email us with your comments or suggestions at editor@myelomasurvival.com.

Any myeloma specialist who would like to participate in this site can submit their multiple myeloma survival rates using the procedure listed in the "Doctor submission" section. If any patient would like to recommend their myeloma specialist,©grp please provide their name,©grp hospital,©grp and email address. We would then email them and invite them to participate. With your help we can "SAVE LIFE"!

If you cannot find a doctor who is located near you from this site,©grp you may run a google or bing search using the key phrase "(insert your state)Multiple Myeloma Treatment Centers",©grp or "(insert your state)Multiple Myeloma Treatment Programs. If you find a Multiple Myeloma specialist on your own,©grp or you want to get more information on one of the doctors listed here,©grp you can google or bing his name as follows: "Dr.(insert the name) Multiple Myeloma Specialist". If you get a lot of great multiple myeloma information,©grp chances are you have someone who is 95% more qualified than your average local oncologist. Just try this with a google search of Dr. Rajkumar,©grp Dr. Barlogie,©grp Dr. Berenson,©grp or Dr. Polumbo.

The myeloma survival rates have been obtained on line or received from myeloma specialists are as follows,©grp and the comparison data from the National Cancer Institute or SEER(Surveillance,©grp Epidemiology and End Results) data base is at the following link: http://seer.cancer.gov/csr/1975_2008/browse_csr.php?section=18&page=sect_18_table.09.html

Western Region

Huntsman Cancer Institute,©grp Salt Lake City,©grp Utah - They list there average life expectancy of 10 years versus the SEER data of 4years. So this is 50% survival at 10 years versus the SEER data of 16.9%. Link: http://www.huntsmancancer.org/patient-care/clinics-and-programs/multiple-myeloma-program/multiple-myeloma-program

Institute for Myeloma & Bone Cancer Research(Dr. Berenson),©grp West Hollywood,©grp CA - In a study of 100 of his patients his 5 year survival rate is 89.7%* vs. the SEER data of 40.9%. That means that your prognosis is 5.7* times better under his treatment than at the average SEER facility. This is truly a remarkable accomplishment. Link: www.berensononcology.com

Seattle Cancer Care Alliance(Fred Hutchinson Cancer Research Center) ,©grp Seattle Washington - Their web site lists a 5 year survival rate of 49% versus the SEER data of 33.9%. Their web site data is aged and should be updated. I believe the current prognosis for survival is much better than this would indicate. Link: http://www.seattlecca.org/scca-survival-rates-multiple-myeloma.cfm

Southern Region

UAMS(Dr. Bart Barlogie),©grp Little Rock AR - The 5 year survival rate for newly diagnosed patients is 74% vs. the SEER data of 43%. This means that you are 2.2* times more likely to be alive under their treatment than the average SEER facility. Link: http://myeloma.uams.edu/upload/docs/Myeloma/MIRT%20Fall%20for%20web.pdf UAMS is one of the only if not the only facility that professes to a CURE for multiple myeloma in 60% of their patients utilizing their Total Therapy 3 protocol. A great link to a debate at UAMS between Dr. Barlogie(UAMS) and Dr. Rajkumar(Mayo) about "Cure vs. Control" is as follows: http://myeloma.uams.edu/news/?sid=28&nid=9241

Midwest Region

Cleveland Clinic,©grp Cleveland,©grp OH - The 5 year survival is 48% vs the SEER data of 40.9%. Note page 21 on the following link: http://my.clevelandclinic.org/Documents/outcomes/2010/outcomes-cancer-2010.pdf

Mayo Clinic(Dr. Martha Lacy),©grp Rochester,©grp MN - The Mayo Clinic Medical Edge Video from July 11,©grp 2011 states that their 3 year survival has improved from 29% to close to 90%. When compared to the SEER rate of 55.6% you are at least 3* times more likely to survive under their treatment than at the average SEER facility. A recent analysis of 290 patients using LD or TD induction and delayed or early stem cell transplant reported equal 4 year survival of 82%* vs the SEER 4 year rate of 50%. Links: http://www.oncologystat.com/journals/journal_scans/Early_Versus_Delayed_Autologous_Transplantation_After_Immunomodulatory_Agents-Based_Induction_Therapy_in_Patients_With_Newly_Diagnosed_Multiple_Myeloma.html and http://getmadcat.com/video/47064/SurvivingMultipleMyeloma.html An outline of their risk adapted treatment program called mSmart can be found at the attached link: http://msmart.org/newly%20diagnosed%20myeloma.pdf

"New Post as of 5/3/12!"
Medical College of Wisconsin(Dr Parameswaran Hari),©grp Milwaukee,©grp Wisconsin - They have provided their 3 year survival of 93.8%* vs. the SEER data of 55.6%. Their 2 year survival was equally impressive at 97.7%* vs. the SEER survival rate of 65%. This is now the best 3 year survival rate for a facility yet presented on this site. This is a remarkable performance and is exactly why this site was developed. This is such a great find,©grp for a center that is not that well know outside the Wisconsin area,©grp and has a myeloma patient population of 1000. I think Milwaukee's little myeloma treasure is no longer their little secret. If you are under the care of Dr Parameswaran Hari at the Medical College of Wisconsin you are 13* times more likely to survive 2 years and 7.2* times more likely to survive 3 years under their care than the average SEER faciltity. Link: http://www.mcw.edu/neoplasticdiseases/faculty/ParameswaranHari.htm#.T6Jn3Kt8Alc

University of Iowa Hospitals and Clinics(Dr. Guido Tricot),©grp Iowa City,©grp Iowa - Their web site lists the expected program average 10 year life expectancy of 50% vs. the SEER data of 16.9%. The expectation is that Dr. Tricot will duplicate his Huntsman results in his new position in Iowa. So you would be 3* times more likely to survive under Dr Tricot's treatment than at the average SEER facility. The link: http://www.uihealthcare.org/2column.aspx?id=228175

Eastern Region

Dartmouth Hitchcock Medical Center - Lebanon,©grp NH - They list a 3 year survival of 76.8 %* with auto transplant vs the SEER data of 55.6%. You are 1.9* times(with auto transplant) more likely to survive under their treatment than at the average SEER facility. Link: http://med.dartmouth-hitchcock.org/quality/metric_BMT/SURVIVAL_-_Multiple_Myeloma/Multiple_myeloma_-_3_year_survival

Europe

No data to date

General International Information

CIBMTR(Center for International Blood and Marrow Transplant Research)Transplant Hospitals - This grouping of 500 hospitals from throughout the world report their transplant data and list the average 2 year survival with auto transplant of approximately 83.9%* vs the SEER data of 65% and a 4 year survival of 69.9%* vs. the SEER data 50.2%. Link : http//www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/Pages/index.aspx (Slide 40 of the summary slides) This listing includes Dana Farber,©grp Mayo,©grp Ceder Sinai,©grp UAMS,©grp Weil Cornell,©grp M.D. Anderson and many many more. In that each listed facility has provided this data to CIBMTR, you should be able to obtain their most current auto transplant survival data for multiple myeloma. The link to this listing is at: http://www.cibmtr.org/About/WhoWeAre/Centers/Pages/index.aspx

Hospitals with Studies or Clinical Trials with exceptional survival**

Southern Region

Mayo,©grp Scottsdale,©grp AZ - A multicenter study of CyBorD or treatment plan that consists of Cyclophophamide,©grp Bortezomib,©grp and dex,©grp with a 3 year survival of 88% vs. the SEER data of 55.6%. So you would be 3.7 times more likely to survive in this trial than in the average SEER facility. An estimate for the survival of those that transplanted and those that did not is 95% transplant and 75% for non transplant. The link is as follows: http://www.myelomabeacon.com/news/2011/12/06/initial-treatment-with-cyclophosphamide-velcade-bortezomib-and-dexamethasone-cybord-compares-favorably-in-terms-of-response-rates-and-side-effects/

UAMS(Dr. Bart Barlogie) Little Rock,©grp AR - A study called TT3 of VTD-PACE with dual transplant and maintenance has a 5 year survival or 78% vs. the SEER data of 40.9%. Under this myeloma treatment protocol your prognosis is 2.7 times better under his care than the average SEER facility. The specifics of this trial are in the attached article: http://jco.ascopubs.org/content/28/7/1209.full

Western Region

No data to date

Midwest Region

Mayo Clinic(Dr Rakjumar) Rochester,©grp MN - This multicenter study of Rd,©grp or Revlimid and low dose dex shows a two year survival of 87% vs the SEER data of 65.6% This is with and without transplant. If you were under this treatment you would be 2.7 times more likely to survive. The data is in the following presentation: http://myeloma.org/pdfs/ash2007_rajkumare4a03.pdf

Eastern Region

Princess Margaret Hospital,©grp Toronto,©grp Canada - A study of CyBorD or Cyclophophamide,©grp Bortezomib,©grp and dex,©grp with a 3 year survival of 88% vs. the SEER data of 55.6%. So you would be 3.7 times more likely to survive in this trial than in the average SEER facility. An estimate for the survival of those that transplanted and those that did not is 95% transplant and 75% for non transplant. The link is as follows: http://www.myelomabeacon.com/news/2011/12/06/initial-treatment-with-cyclophosphamide-velcade-bortezomib-and-dexamethasone-cybord-compares-favorably-in-terms-of-response-rates-and-side-effects/

Dana Farber Cancer Institute(Dr Ken Anderson),©grp Boston Mass. - A multicenter study of RVD or Revlimid Velcade Dex with and without transplant provides a 18 month survival of 97% for all patients(with and without transplant) vs. an estimate of a SEER value between 1 and 2 years of 71%. This would be almost 10 times better for the patients in this trial. The data is available in the following link: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=52410

Weill Cornell(Dr. Ruben Niesvizky) ,©grp NY,NY - BiRd or Biaxin,©grp lenalidomide,©grp and low dose dexamethasone had a 3 year survival of 89.7% vs. the SEER data of 55.6%. If part of this multicenter trial you are 4 times more likely to survive. The data is available in the following link: http://www.ncbi.nlm.nih.gov/pubmed/20645430

Europe

University Hospital ( Dr. Jesús San Miguel) Salamanca,©grp Spain - This multicenter trial of VMP Velcade-melpahalan-Predisone for older transplant ineligible  patients provided a 5 year survival of 46% vs. the SEER data of 40.9%. The link is: http://ash.confex.com/ash/2011/webprogram/Paper37551.html

University of Torino(Dr. Antonio Palumbo) Torino,©grp Italy - This muticenter study of VMPT-VT or Velcade-melphalan-predisone-thalidomide with Velcade- thalidomide maintenance shows a 3 year survival of 89% vs. the SEER data of 55.6%. This is with older transplant ineligible patients.  If you were in this trial you would be 4 times more likely to survive than the average.  Link:   http://jco.ascopubs.org/content/early/2010/10/07/JCO.2010.29.8216.full.pdf   Another study with PAD(Bortezomib,©grp doxorubicin,©grp and dex),©grp two transplants,©grp LP consolidation and L maintenance had a two year survival of 86% vs the SEER of 65.6%. Link: http://jco.ascopubs.org/content/28/5/800.full.pdf

*SEER numbers are based on Relative Survival(myeloma deaths only) whereas others are based on Observed Survival(all
deaths) and as a result these numbers must be adjusted upward to be comparable to the SEER data. See page 3 for more
information on methodology.

**All the drugs in the above trials have been approved for use in multiple myeloma in the USA and do not require clinical trials for use,©grp however they may not be approved in every country.

*This multiple is computed by taking the the death rate of the SEER data (1-.41) and dividing it by the death rate of the hospital listed above(1-.897) or 5.7 times. Another way to look at it is to say of 100 people 59 have died in the SEER facility's in 5 years,©grp while only 10.3 have died in the listed hospital's care. So you are 5.7 times (59/10.3) more likely to be alive in the listed hospital. This can be confused with a comparison of the survival rates. The survival rates are only different by 2.18 times or 89.7/41, which I believe is less valuable as a measure for the multiple myeloma patient community.

Excellent Multiple Myeloma Resources

International Myeloma Foundation(IMF) - http://myeloma.org/Main.action

Multiple Myeloma Research Foundation(MMRF) http://www.themmrf.org/

On Line Patient to Patient Support - http://www.acor.org/myeloma.html

LLS(The Leukemia & Lymphoma Society) $10,000 Myeloma Co Pay assist -
http://www.lls.org/diseaseinformation/getinformationsupport/financialmatters/copayassistance/

Managing Myeloma - http://www.managingmyeloma.com/

Myeloma Beacon - http://www.myelomabeacon.com/

Living with Multiple Myeloma - http://multiplemyelomablog.com/

Cancer Care Copay assist $3500 - http://www.cancercarecopay.org/apply.html